The companies provided no specific reason for the abrupt termination of the deal, which would have served as the primary vehicle for Ignite Proteomics to debut on the stock exchange. Despite the dissolution, Copley Acquisition remains active in its search for a new target. The special purpose acquisition company faces a deadline of Nov. 2 to secure a fresh merger agreement, though its governing documents allow for potential extensions beyond that date.
Copley Acquisition and Ignite Proteomics Scrap Merger Deal
A planned path to the public markets has collapsed for Ignite Proteomics Holdings after the oncology firm and its blank-check partner, Copley Acquisition Corp., mutually agreed to terminate their merger agreement. The decision, formalized in a Tuesday filing with the Securities and Exchange Commission, ends a partnership announced only last June.
Comments (0)
No comments yet. Be the first!